Fujifilm Biotechnologies said its commercial-scale cell culture manufacturing facility in Holly Springs, North Carolina was selected by FDA for the PreCheck Pilot Program, aimed at strengthening U.S. pharmaceutical manufacturing readiness. The company’s planned expansion at the site and the ability to produce drug substance for products such as argenx’s Vyvgart franchises underscore a broader push to scale cell-based manufacturing capacity and strengthen release capabilities through QC investments.